Understand the source comparison
Cerebrolysin vs Citicoline, Piracetam, and Other Neuroprotective Agents — Mechanism and Evidence
| Agent | Primary Mechanism | Blood-Brain Barrier Penetration | Acute Stroke Evidence (RCT) | Typical Dose | Clinical Availability | Bottom Line ||—|—|—|—|—|—|| Cerebrolysin | Neurotrophic peptides (BDNF/NGF mimetics). Mitochondrial stabilization, anti-apoptot
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Agent | Primary Mechanism | Blood-Brain Barrier Penetration | Acute Stroke Evidence (RCT) | Typical Dose | Clinical Availability | Bottom Line ||—|—|—|—|—|—|| Cerebrolysin | Neurotrophic peptides (BDNF/NGF mimetics). Mitochondrial stabilization, anti-apoptotic signaling | Yes (MW <10 kDa peptides cross via receptor-mediated transcytosis) | CASTA trial: 1,070 patients, significant mRS improvement at 90 days | 30mL IV daily × 21 days | Prescription in EU/Asia; research-grade available | Most robust Phase III evidence for functional recovery in acute ischemic stroke || Citicoline (CDP-choline) | Phospholipid precursor. Membrane repair, acetylcholine synthesis | Yes (crosses as choline and cytidine, reassembled intracellularly) | ICTUS trial: 2,298 patients, no significant benefit vs placebo | 1,000–2,000mg oral daily | OTC supplement | Large trial showed null result; mechanism plausible but efficacy unproven || Piracetam | Modulates AMPA receptors, increases membrane fluidity | Partial
- Cerebrolysin stands apart because it addresses multiple pathways simultaneously. Not just antioxidant activity or single-receptor modulation, but direct neurotrophic support that mimics the body's endogenous repair signals. Citicoline failed its largest Phase III trial (ICTUS) despite mechanistic plausibility, largely because oral absorption and conversion to active metabolites introduces too much pharmacokinetic variability. Cerebrolysin's IV route bypasses this entirely.
- Our team has reviewed peptide stability data across these compounds. Cerebrolysin's multi-peptide composition creates redundancy: even if one fraction degrades during storage, other bioactive components remain therapeutically relevant. Single-molecule agents like edaravone lack this built-in stability buffer.